Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8135185rdf:typepubmed:Citationlld:pubmed
pubmed-article:8135185lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:8135185lifeskim:mentionsumls-concept:C0021756lld:lifeskim
pubmed-article:8135185lifeskim:mentionsumls-concept:C0023434lld:lifeskim
pubmed-article:8135185lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:8135185lifeskim:mentionsumls-concept:C1318876lld:lifeskim
pubmed-article:8135185lifeskim:mentionsumls-concept:C1571148lld:lifeskim
pubmed-article:8135185pubmed:issue3lld:pubmed
pubmed-article:8135185pubmed:dateCreated1994-4-18lld:pubmed
pubmed-article:8135185pubmed:abstractTextB-cell chronic lymphocytic leukemia (B-CLL) is typically a low-grade neoplasm with a diploid DNA index and low proliferative activity. Interleukin-2 receptor (IL-2R/CD25) positivity often indicates increased proliferative activity and activation in both T and B lymphocytes. The argyrophilic nucleolar organizer regions (AgNORs) are loops of DNA identified by a silver staining technique and have been correlated with ploidy and proliferative activity. Two distinct AgNOR counting methods have been previously shown to correlate with DNA ploidy and proliferative activity, respectively: the mean AgNOR count (mAgNOR) correlates more with ploidy, and the percentage of nuclei with > or = 5 AgNORs/nucleus (pAgNOR) reflects proliferative activity. We studied bone marrow specimens from 32 patients with B-CLL using both anti-IL-2R on the marrow aspirates and the AgNOR silver stain on marrow biopsy specimens, applying both AgNOR counts. All tumors were CD5+, CD19+, and CD19/CD20+. Sixteen tumors were IL-2R- (< 20% IL-2+ B cells), and 16 were IL-2R+ (> or = 20% IL-2R+ B-cells). No significant difference in morphology of bone marrow involvement was noted in the two groups. A male predominance was noted in the IL-2R+ group of patients (3:1). There was also a preponderance of lambda light chain expression in the IL-2R+ tumors (11/16) compared with the IL-2R- cases (5/16). Except for two cases, all tumors had mAgNOR counts within the diploid range (< 2.4). The 16 IL-2R- tumors had pAgNOR in the range of 0% to 7% (mean, 2.31 +/- 2.18 standard deviation), whereas the IL-2R+ tumors had pAgNOR ranging from 6% to 15% (mean, 10.20 +/- 2.70 standard deviation; P < .0001). This finding suggests that IL-2R+ B-CLL might represent a subgroup of tumors with higher proliferative activity.lld:pubmed
pubmed-article:8135185pubmed:languageenglld:pubmed
pubmed-article:8135185pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135185pubmed:citationSubsetAIMlld:pubmed
pubmed-article:8135185pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135185pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8135185pubmed:statusMEDLINElld:pubmed
pubmed-article:8135185pubmed:monthMarlld:pubmed
pubmed-article:8135185pubmed:issn0002-9173lld:pubmed
pubmed-article:8135185pubmed:authorpubmed-author:KeatingM JMJlld:pubmed
pubmed-article:8135185pubmed:authorpubmed-author:MouradW AWAlld:pubmed
pubmed-article:8135185pubmed:authorpubmed-author:HuhY OYOlld:pubmed
pubmed-article:8135185pubmed:authorpubmed-author:PughW CWClld:pubmed
pubmed-article:8135185pubmed:issnTypePrintlld:pubmed
pubmed-article:8135185pubmed:volume101lld:pubmed
pubmed-article:8135185pubmed:ownerNLMlld:pubmed
pubmed-article:8135185pubmed:authorsCompleteYlld:pubmed
pubmed-article:8135185pubmed:pagination300-4lld:pubmed
pubmed-article:8135185pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:meshHeadingpubmed-meshheading:8135185-...lld:pubmed
pubmed-article:8135185pubmed:year1994lld:pubmed
pubmed-article:8135185pubmed:articleTitleCell kinetic analysis of interleukin-2 receptor-tested chronic lymphocytic leukemia using the AgNOR silver stain.lld:pubmed
pubmed-article:8135185pubmed:affiliationDepartment of Pathology, University of Texas M.D. Anderson Cancer Center, Houston.lld:pubmed
pubmed-article:8135185pubmed:publicationTypeJournal Articlelld:pubmed